INCY News and Press, Incyte Corporation From 03/23/21

Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of patients with unresectable biliary tract cancer (BTC)...

Incyte (INCY) announces results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care ((SoC)) versus SoC in patients on mechanical ventilation with COVID-19 associated Acute Respiratory Distress Syndrome ((ARDS)).The study di...

- Improvement in mortality for each dose compared to placebo, while trending toward positive, was not statistically significant for the overall study population - Significant improvement in mortality seen in U.S. study participants at both doses, and in the overall population ...

With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...

Despite growing by more than 600% over the past 10 years (more than doubling the S&P 500 's returns in the process), over the past five years, biopharmaceutical company Incyte (NASDAQ: INCY) has barely budged. In that time, the company's shares are up approximately 10%. ...

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021. “At AACR 2021, we look f...

Eli Lilly (LLY) and Incyte (INCY) announce top-line results from Phase 3 BRAVE-AA2 study, evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata ((AA)).Both doses of baricitinib met the primary efficacy endpoint at Week 36, demons...

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial - Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA PR Newswire INDIANAPOLI...

BiotechValley Insights is initiating coverage of ACRS with a "Bullish" rating. ATI-450 is a novel oral MK2 inhibitor that demonstrated comparable efficacy and superior safety over Jak inhibitors during Ph2. The oral route of administration offers a superior convenience over biological...

This investment strategy holds a maximum of 50 consensus stock picks from 40 hedge funds with more than $3,500 million Assets Under Management. Changes in the holdings occur only every three months when the end of the quarter 13F filings become public information; the latest date was ...